might further substantiate the flexibility and efficiency of our synthetic scheme previously developed for 1 and its congener. We wish to report here the details of synthesis of enantiomeric pairs of 3, 4, 5 and 6 and the in vitro antibacterial and mammalian type I FAS inhibitory activity of these pairs. The results clearly disclosed novel aspects of the structure-activity relationships of the C 5 
-position of TLM and led us to explore ent-3-demethyl-5-(alk-2-enyl)-TLM (ent-4d) and ent-5-[(E)-cycloalk-2-enylidenemethyl]-TLM (ent-5c).
The former congener ent-4d exhibited mammalian type I FAS inhibitory activity equal to that of C75, a potent inhibitor previously revealed, 15, 29) and twice that of ent-2 previously reported. 26, 27) The latter congener ent-5c showed type I FAS inhibitory activity that was a little less potent than that of C75 and a little more potent than that of ent-2. All the congeners synthesized in these studies were found to completely lack in vitro antibacterial activity.
Results and Discussion Synthesis of 5-Vinylthiolactomycins [5-(Alk-2-enyl)-TLMs], Their 3-Demethyl Congeners [3-Demethyl-5-(alk-2-enyl)-TLMs] and Their Enantiomers
Following the synthetic scheme previously established, 26) we commenced the synthesis of (R)-5-(alk-2-enyl)-TLMs and (R)-3-demethyl-5-(alk-2-enyl)-TLMs (3a-f, 4a-f) (Chart 1). Among a,b-unsaturated carboxylic acids 8a-f used as the starting materials for the synthesis of 3a-f and 4a-f, 8a-c were commercially available while 8d-f were prepared from the corresponding aldehydes 7d-f by a sequential Horner-Wadsworth-Emmons reaction and alkaline hydrolysis in a method similar to that previously reported. 26, 27) 8a-f were transformed into (S)-N-acyloxazolidin-2-ones 9a-f by first treating them with pivaloyl chloride, and the resulting mixed anhydrides were allowed to react with (S)-4-benzyloxazolidin-2-one. 30) The preliminarily successful synthesis of known ent-3b 22) by the use of (R)-4-benzyloxazolidin-2-one as a chiral source allowed us to select (S)-4-benzyloxazolidin-2-one as a chiral auxiliary for the synthesis of 3a-f and 4a-f (vide infra).
With 9a-f in hand, we next examined the electrophilic deconjugative asymmetric a-sulfenylation using S-3,3-dimethoxypropyl thiosulfonate 10 as a sulfenylating agent, which constitutes the key synthetic step. Based on our previous results, 26, 27) we expected 10 to be as an excellent electrophilic agent with the functional group readily transformable into a thiol. 10 was prepared starting with 3-bromopropionaldehyde dimethylacetal according to our previously reported procedure. 26, 27) First, to secure the deconjugative asymmetric a-sulfenylation of 9 with 10, the sulfenylation was examined by using 9b as a model substrate and by employing various disilazide bases in a manner similar to that for the synthesis of 1 ( Table 1) . We found that the deconjugative asymmetric a-sulfenylation of 9b took place smoothly by making use of potassium bis(trimethylsilyl)amide (KHMDS) as a base in the absence of hexamethylphosphoramide (HMPA), providing the a-sulfenylated compound 11b in a stereoselective and regioselective manner along with the other a-sulfenylated product, 24b diastereomeric to 11b, and the g-sulfenylated product, 25b (Table 1 , run 3). In our previous synthesis of 1, 26, 27) the deconjugative asymmetric asulfenylation was effected using sodium bis(trimethylsilyl)-amide (NaHMDS) in the presence of HMPA. However, unexpectedly, when 9b was treated under the same conditions (Table 1 , run 1), the sulfenylation was found to occur in a lower yield along with a lower diastereo-and regioselectivity. The sulfenylation of 9a, c-f also showed a low selectivity similar to that of 9b. It was anticipated that the stereo and/or electronic difference between the dienolate derived from 9b and the trienolate I (Fig. 2) presumed to be involved in the synthesis of 1 might make the transition state of sulfenylation different even under the same condition (Table 1 , run 1). Thus it was presumed that the reaction condition used for the synthesis of 1 would not be directly applied to the sulfenylation of 9b. Therefore, the sulfenylation of 9b was next examined in the absence of HMPA in order to improve the diastereo-and regioselectivity (Table 1 , run 2). Gratifyingly, both diastereoselectivity of 11b against 24b and the regioselectivity of 11b against 25b were dramatically improved. Moreover, KHMDS was more effective than NaHMDS to further increase the chemical yield and regioselectivity, affording 11b, 24b and 25b in 74%, 6% and 8% yields, respectively (Table 1 , run 3). Separation of 11b, 24b and 25b was accomplished by flash column chromatography. While 25b was always obtained as a mixture of the two diastereomers, their separation was not attempted. The other (S)-N-acyloxazolidin-2-one 9a, c-f were subjected to the same conditions as those optimized using 9b, producing the a-sulfenylated compounds 11a, c-f in the yields shown in Chart 1 along Table 1 . Deconjugative Asymmetric a-Sulfenylation of the (S)-N-Acyloxazolidin-2-one 9b with S-3,3-Dimethoxypropyl Thiosulfonate 10
Run
Base Additive (eq)
Yield of the a-sulfenylated products Yield of 25b (%) a)
11b (%) 24b (%) with the corresponding diastereomers 24a, c-f. The absolute stereochemistry of the 2Ј-position of 11b was rigorously assigned to have the (R)-configuration based on the preliminarily successful synthesis of known ent-3b 22) from ent-11b. The 1 H-NMR spectra of 11a, c-f which were quite similar to that of 11b, clearly supported that 11a, c-f bear the same (R)-configuration as that of 11b.
31) Based on these preliminary results, (S)-4-benzyloxazolidin-2-one was employed as a chiral auxiliary for preparing 3 and 4 instead of its (R)-enantiomer (vide supra).
Unlike the previous case, in which (R)-N-acyloxazolidin-2-one derived from (R)-4-benzyloxazolidin-2-one provided the (R)-a-sulfenylated product by way of the non-chelated (E)-trienolate (I), 26, 27) the deconjugative asymmetric asulfenylation of (S)-N-acyloxazolidin-2-one 9a-f prepared from (S)-4-benzyloxazolidin-2-one gave the (R)-sulfenylated products 11a-f. The latter reaction, carried out in the absence of HMPA, was expected to proceed through the chelated (E)-dienolate (II) due to the absence of HMPA with the sterically less hindered a face approach of 10 ( Fig. 2) .
As shown in Chart 1, the a-sulfenylated products 11a-f were transformed into benzyl esters 12a-f by imide-ester exchange using titanium benzyloxide [Ti(OBn) 4 ]. 32, 33) Acidic hydrolysis of the dimethyl acetal moieties in 12a-f produced aldehydes 13a-f. The retro-Michael reaction of 13a-f using cesium carbonate (Cs 2 CO 3 ) as a base and subsequent treatments of the resulting cesium thiolates with propionyl or acetyl chloride, provided a-acylthio esters 14a-f or 15a-f. According to the reported protocol, 23) the Dieckmann condensation of 14a-f and 15a-f using lithium bis(trimethylsilyl)amide (LiHMDS) as a base furnished (R)-5-(alk-2-enyl)-TLM and their 3-demethyl congeners 3a-f and 4a-f. Using the identical synthetic scheme as described above, the enantiomers of 3a-f and 4a-f (ent-3a-f, ent4a-f) were synthesized from ent-9a-f prepared from 8a-f and (R)-4-benzyloxazolidin-2-one.
Synthesis of 5-[(E)-Cycloalk-2-enylidenemethyl] Thiolactomycins {5-[(E)-Cycloalk-2-enylidenemethyl]-TLMs}, Their 3-Demethyl Congeners {5-[(E)-Cycloalk-2-enylidenemethyl]-3-demethyl-TLMs} and Their Enantiomers
Next, in order to elucidate the relationship between the flexibility of the C5-isoprenoid 1,3-diene moiety and biological activity, the synthesis of enantiomeric pairs of 5-[(E)-cycloalk-2-enylidenemethyl]-TLMs 5a-c and their 3-demethyl congeners 6a-c was examined by employing a,bunsaturated carboxylic acids 17a-c as starting materials in a method similar to that for the synthesis of 3 and 4 described in 2.2. Compounds 17a-c were prepared from a,b-unsaturated aldehydes 16a-c by a sequential Horner-WadsworthEmmons reaction and alkaline hydrolysis (Chart 2). 16a was commercially available, and 16b, c were prepared from 1-nitromethylcycloheptene 34) and NЈ-cyclooctylidene-4-methylbenzenesulfonohydrazide, 35) respectively, according to the reported procedures. 34, 35) Activation of 17a-c with pivaloyl chloride followed by treatment of the formed mixed anhydrides with (R)-4-benzyloxazolidin-2-one afforded (R)-Nacyloxazolidin-2-ones 18a-c. In this case, (R)-4-benzyloxazolidin-2-one was selected as a chiral source by taking account not only of the reaction conditions for deconjugative asymmetric a-sulfenylation but also the absolute configuration of the a-sulfenylated product (vide infra).
With 18a-c in hand, we attempted the key deconjugative asymmetric a-sulfenylation by employing the conditions used for the sulfenylation reaction of the corresponding synthetic intermediate of 1. 26, 27) Thus, treatments of 18a with 3,3-dimethoxypropyl methanethiosulfonate 10 using NaH-MDS as a base in the presence of HMPA led to the deconjugative asymmetric a-sulfenylation, giving rise to the asulfenylated product 19a highly diastereoselectively and in excellent yield (Table 2 , run 1). 36) However, efficient sulfenylation reactions of 18b, c were not effective under the same conditions as those for 18a (Table 2 , run 2, 4). It was antici- 922 Vol. 57, No. 9
(a) (EtO) 2 P(O)CHMeCO 2 Et, tBuOLi, hexane, rt, then 10% NaOH aq., EtOH, 50°C, 92% for 8d, 100% for 8e, 100% for 8f; (b) tBuCOCl, Et 3 N, THF, Ϫ15°C, then LiCl, (S)-4-benzyoxazolidin-2-one, rt 83% for 9a, 96% for 9b, 90% for 9c, 87% for 9d, 96% for 9e, 93% for 9f; (c) KHMDS, THF, Ϫ78°C, then S-3,3-dimethoxypropyl methanethiosulfonate (10), Ϫ78 to 0°C, 18% for 11a, 74% for 11b (see Table 1 ), 60% for 11c, 50% for 11d, 61% for 11e, 51% for 11f; (d) Ti(OiPr) 4 , BnOH, 70°C, 82% for 12a, 88% for 12b, 95% for 12c, 96% for 12d, 89% for 12e, 85% for 12f; (e) 6% HCl aq., THF, rt, 98% for 13a, 98% for 13b, 98% for 13c, 93% for 13d, 66% for 13e, 76% for 13f; (f) Cs 2 CO 3 , EtOH, 4°C, then CH 3 CH 2 COCl or CH 3 COCl, Et 3 N, CH 2 Cl 2 , 4°C, 81% for 14a, 74% for 14b, 50% for 14c, 61% for 14d, 62% for 14e, 50% for 14f, 69% for 15a, 68% for 15b, 52% for 15c, 73% for 15d, 48% for 15e, 36% for 15f; (g) LiHMDS, THF, Ϫ78°C-rt, 70% for 3a, 74% for 3b, 65% for 3c, 64% for 3d, 64% for 3e, 33% for 3f, 86% for 4a, 89% for 4b, 89% for 4c,77% for 4d, 87% for 4e, 76% for 4f. pated that the abstraction of the e-protons of 18b and 18c might be more difficult than that of 18a because of steric and/or electronic differences between 18b, c and 18a, and that the trienolates derived from 18b, c were more unstable than that produced from 18a. Accordingly, the amount of base and the use of other additive were next examined. Thus, the sulfenylation of 18b produced the a-sulfenylated compound 19b in 64% yield even if the increased amounts of base and HMPA were used (Table 2, run 3). As for the sulfenylating reaction of 18c, it was found to give a lower yield of 19c under conditions similar to those for 18a, b. Experimentation revealed that the use of KHMDS (1.0 eq) as a base in the presence of 18-crown-6 was more effective, giving rise to 19c in a highly diastereoselective manner in a 68% yield (Table 2 , run 5). In the deconjugative asymmetric asulfenylation of 18a-c, we always observed the formation of small amounts of the a-sulfenylated products 26a-c diastereomeric to 19a-c and the a-sulfenylated products 27a-c bearing a (Z)-configuration. The formation ratios of 19a-c, 26a-c to 27a-c estimated by the 1 H-NMR spectra and/or HPLC analyses are summarized in Table 2. 37) Pure samples of 19a-c were obtained by sequential separation with column chromatography and HPLC.
The structures of 19a-c, 26a-c, and 27a-c were rigorously determined by their 1 H-NMR spectra. Thus, the nuclear Overhauser effect spectroscopy (NOESY) spectra of 19a-c and 26a-c were observed between olefinic C-3ЈH and C-5ЈH. On the other hand, the structures of the 27a-c were assigned by the NOESY spectra observed between C-3ЈH and C-9ЈH, and not between C-3ЈH and C-5ЈH. The absolute stereochemistries of newly created asymmetric centers for 19a-c were assigned to have an (R)-configuration by comparing their 1 H-NMR spectra with that of the corresponding a-sulfenylated product for the synthesis of 1 (vide supra). 26, 38) A plausible mechanism of deconjugative asymmetric a-sulfenylation of 18 was anticipated to be very similar to that proposed for the synthesis of 1 because HMPA or 18-crown-6 was used as an additive in these reactions (see, Fig. 2, I ).
Following the same synthetic scheme as previously described for the preparation of 3a-f and 4a-f, (R)-5-[(E)-cycloalk-2-enylidenemethyl]-TLMs 5a-c and their 3-demethyl congeners 6a-c were readily prepared from the asulfenylated products 19a-c isolated in pure states by HPLC separation. Thus, as shown in Chart 2, the sequential imide-ester exchange of 19a-c, acidic hydrolysis of 20a-c, retro-Michael reaction of 21a-c, acylation with propionyl or acetyl chloride and Dieckmann condensation of 22a-c and 23a-c furnished 5a-c and 6a-c, respectively. By the same synthetic scheme, the enantiomers of 5a-c and 6a-c (ent-5a-c, ent-6a-c) were prepared from ent-19a-c obtained from 17a-c and (S)-4-benzyloxazolidin-2-one.
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(a) (EtO) 2 P(O)CHMeCO 2 Et, tBuOLi, hexane, rt, then 10% NaOH aq., EtOH, 50°C, 88% for 17a, 59% for 17b, 81% for 17c; (b) tBuCOCl, Et 3 N, THF, Ϫ15°C, then LiCl, (R)-4-benzyloxazolidin-2-one, rt, 81% for 18a, 78% for 18b, 71% for 18c; (c) see Table 2 ; (d) Ti(OiPr) 4 , BnOH, 70°C, 76% for 20a, 69% for 20b, 87% for 20c; (e) 6% HCl aq., THF, rt, 87% for 21a, 92% for 21b, 96% for 21c; (f) Cs 2 CO 3 , EtOH, 4°C, then CH 3 CH 2 COCl or CH 3 COCl, Et 3 N, CH 2 Cl 2 , 4°C, 66% for 22a, 68% for 22b, 73% for 22c, 68% for 23a, 63% for 23b, 67% for 23c; (g) LiHMDS, THF, Ϫ78 °C-rt, 84% for 5a, 89% for 5b, 66% for 5c, 99% for 6a, 64% for 6b, 46% for 6c. Antibacterial Activity and Type I FAS Inhibitory Activity of Enantiomeric Pairs of TLM Congeners After 3a-f, ent-3a-f, 4a-f, ent-4a-f, 5a-c, ent-5a-c, 6a-c and ent-6a-c were synthesized, 39) their in vitro antibacterial activities against various strains of bacteria 40) and their inhibitory activities against mammalian type I FAS 41) were evaluated similarly to those for 1, 2 and their enantiomers ent-1 and ent-2. 1, 27) Unlike the case in previous reports, 1, 25) all the tested compounds lacked in vitro antibacterial activity against all the tested strains of bacteria even though 3a-f, 4a-f, 5a-c and 6a-c bear the same (R)-configurations as 1 and 2. Therefore, the results on the inhibitory activity against only mammalian type I FAS are summarized in Table  3 along with those for 1, ent-1, 2, ent-2 and C75, a potent inhibitor against type I FAS so far reported. 15, 29) As for mammalian type I FAS inhibitory activity, 14 compounds-ent-4c, ent-3d, ent-4d, ent-3e, 4e, ent-4e and 4f, each of which has a vinyl moiety at the C 5 -position, and ent6a, ent-5b, 6b, ent-6b, ent-5c, 6c and ent-6c, whose isoprenoid 1,3-diene moieties are involved in a ring systemwere found to exhibit mammalian type I FAS inhibitory activity at levels equal to or more potent than that recorded for ent-2. Especially, the inhibitory activity of ent-4d was almost equal to that of C75 and more than twice that of previously synthesized ent-2. 26, 27) Summing up the results for 5-(alk-2-enyl)-TLMs and their 3-demethyl congeners shown in Table  3 , it might be concluded that, in general, the (S)-enantiomers show more potent type I FAS inhibitory activity than the corresponding (R)-enantiomers (see the cases for R 2 ϭEt and nPr) and that the activity of C 3 -demethyl congeners is higher than that of the corresponding C 3 -methyl compounds (see the cases for R 2 ϭEt, nPr and nBu). As for the length of the C 5 -alkenyl moiety, type I FAS inhibitory activity seems to gradually increase until the number of carbon atoms reaches 5, above which it slightly decreases. This tendency was most apparent for ent-4a-f. In addition, it was found that, as the C 5 -alkenyl side chain becomes longer, the absolute configuration renders less effect on type I FAS inhibitory activity (see the cases for R 2 ϭnPr, nBu and nHex). More potent type I FAS inhibitory activity was clearly shown by ent-5b, 6b and ent-5c. The activity of the most potent ent-5c was a little less than that of C75 and almost twice that of ent-2. 26, 27) However, it appeared that locking the s-trans configuration of isoprenoid the 1,3-diene moiety as a consequence of the involvement in a ring system obviously decreased the tendency to separate the biological activity due to the difference in the absolute configuration at the C 5 -position as previously shown for 1, ent-1, 2 and ent-2.
1,27)

Conclusion
In summary, we have succeeded in synthesizing 12 enantiomeric pairs of 5-(alk-2-enyl)-TLMs (3a-f, ent-3a-f, 4a-f, ent-4a-f) and six enantiomeric pairs of 5-[(E)-cycloalk-2-enylidenemethyl]-TLMs (5, ent-5, 6, ent-6) by employing our efficient synthetic route previously explored for the total synthesis of TLM (1), 3-demethyl congener (2), and their enantiomers (ent-1, ent-2).The examination of in vitro antibacterial activity revealed that the free-rotational isoprenoid 1,3-diene moiety and the (R)-configuration at the C 5 -position are essential for 1 and its congeners to exhibit in vitro antibacterial activity. As for mammalian type I FAS inhibitory activity, (S)-3-demethyl-TLM (ent-4d) exhibited a level of inhibitory activity against mammalian type I FAS that was almost equal to that of C75, a potent inhibitor previously reported and more than twice that of previously synthesized ent-2.
11,12) 5-[(E)-Cycloalk-2-enylidenemethyl]-TLM (ent-5c), in which the isoprenoid 1,3-diene moiety is locked into an s-trans configuration as a consequence of its involvement in a ring system, was found to exhibit slightly less inhibitory activity than C75 and almost twice that of the previ- Table 3 . In Vitro Mammalian Type I FAS Inhibitory Activity of Enantiomeric Pairs of TLM and Its Congeners (1, ent-1, 2, ent-2, 3a-f, ent-3a-f, 4a-f , ent-4a-f, 5a-c, ent-5a-c, 6a-c, ent-6a-c). (E)-2-Methyloct-2-enoic Acid (8e) Treatments of n-hexanal (5.8 ml, 45.1 mmol) with triethyl 2-phosphonopropionate (12.0 g, 49.4 mmol) in a manner similar to that described for the preparation of 8d, afforded 8e (6.48 g, 92%) as a mixture of (E,Z) isomer (E/Zϭ8 : 1). This sample was directly used for the next acylation without separation of (E)-and (Z)-isomer. 1 (E)-2-Methyldec-2-enoic Acid (8f) Treatments of n-octanal (9.0 ml, 54.7 mmol) with triethyl 2-phosphonopropionate (14.0 g, 57.6 mmol) in the same manner as described for the preparation of 8d, afforded 8f (10.75 g, 100%) as a mixture of (E,Z) isomer (E/Zϭ8 : 1). This sample was directly used for the next acylation without separation of (E)-and (Z)-isomer. 1 (S,E)-4-Benzyl-3-(2-methylpent-2-enoyl)oxazolidin-2-one (9b) and Its Enantiomer (ent-9b) (a) Preparation of 9b: To a solution of (E)-2-methylpent-2-enoic acid (1.14 g, 9.79 mmol) and Et 3 N (3.0 ml, 21.5 mmol) in THF (50 ml), pivaloyl chloride (1.65 ml, 9.98 mmol) was added dropwise at Ϫ15°C, and the resulting mixture was stirred at the same temperature for 15 min. Lithium chloride (500 mg, 11.8 mmol) and (S)-4-benzyloxazolidin-2-one (2.10 g, 11.6 mmol) were added to the mixture at the same temperature, and the stirring was continued for 13 h at room temperature. After quenching the reaction by adding saturated aqueous ammonium chloride solution (30 ml), the mixture was extracted with AcOEt (30 mlϫ3). The organic extracts were combined, washed with saturated aqueous sodium hydrogen carbonate solution (50 ml) and brine (50 ml), dried over anhydrous Na 2 (S,E)-4-Benzyl-3-(2-methylhex-2-enoyl)oxazolidin-2-one (9c) and Its Enantiomer (ent-9c) (a) Preparation of 9c: Treatments of (E)-2-methylhex-2-enoic acid (1.5 ml, 11.9 mmol) in a manner similar to that described for the preparation of 9b, afforded 9c (3. 1 mmol) in a manner similar to that described for the preparation of 9b, afforded oily 9f (18.6 g, 93%) as a mixture of (E,Z) isomer (E/Zϭ18 : 1 To a solution of 9b (110 mg, 0.402 mmol) in THF (2.0 ml), KHMDS (0.5 mol/l solution in toluene, 0.96 ml, 0.48 mmol) was added dropwise at Ϫ78°C, and the resulting mixture was stirred at the same temperature for 30 min. A solution of 10 (130 mg, 0.607 mmol) in THF (0.4 ml) was added to the reaction mixture at the same temperature, and the resulting mixture was allowed to slowly warm to 0°C. After quenching the reaction by adding saturated aqueous ammonium chloride solution (10 ml), the mixture was extracted with AcOEt (10 mlϫ3). The organic extracts were combined, washed with brine (10 ml), dried over anhydrous Na 2 SO 4 , filtered, and then concentrated in vacuo. Flash column chromatography (hexane/AcOEtϭ4 : 1) of the residue gave 11b (121 mg, 74%), its (2ЈS)-diastereomer 24b (10 mg, 6%) and the g-sulfenylated product 25b (13 mg, 8%), all as an oil. (b) Preparation of ent-11b: Compound ent-11b (1.67 g, 56%) was prepared as a colorless oil from ent-9b (900 mg, 3.01 mmol) in the same manner as described in (a). 42) [a] D 25 Ϫ53.6 (cϭ0.8, MeOH). 
Deconjugative Asymmetric a a-Sulfenylation of (S)-and (R)-4-Benzyl-3-(2-methylbut-2-enoyl)oxazolidin-2-one (9a, ent-9a). (S)-4-Benzyl-3-[(R)-2-(3,3-dimethoxypropylthio)-2-methylbut-3-enoyl]oxazolidin-2-one (11a) and Its Enantiomer (ent-11a) (a) Preparation of 11a:
Treatments of 9a (4.10 g, 15.8 mmol) in a manner similar to that described for the preparation of 11b, afforded 11a (1.14 g, 18%) as a colorless oil. 42) [a] D 27 ϩ52.1 (cϭ0.5, MeOH). 
Deconjugative Asymmetric a a-Sulfenylation of (S,E)-and (R,E)-4-Benzyl-3-(2-methylhex-2-enoyl)oxazolidin-2-one (9c, ent-9c). (S)-4-Benzyl-3-[(R,E)-2-(3,3-dimethoxypropylthio)-2-methylhex-3-enoyl]oxazolidin-2-one (11c) and Its Enantiomer (ent-11c) (a) Preparation of 11c:
Treatments of 9c (2.01 g, 6.99 mmol) in a manner similar to that described for the preparation of 11b, afforded 11c (1.78 g, 60%) as a colorless oil. 42) [a] D 27 ϩ54.1 (cϭ0.7, MeOH). 
Deconjugative Asymmetric a a-Sulfenylation of (S,E)-and (R,E)-4-Benzyl-3-(2-methylhept-2-enoyl)oxazolidin-2-one (9d, ent-9d). (S)-4-Benzyl-3-[(R,E)-2-(3,3-dimethoxypropylthio)-2-methylhept-3-enoyl]oxazolidin-2-one (11d) and Its Enantiomer (ent-11d) (a) Preparation of 11d:
Treatments of 9d (2.19 g, 7.27 mmol) in a manner similar to that described for the preparation of 11b, afforded 11d (1.59 g, 50%) as a colorless oil. 42) [a] D 27 ϩ50.6 (cϭ1.0, MeOH Compound ent-11e (4.57 g, 80%) was prepared as a colorless oil from ent-9e (4.00 g, 12.7 mmol) in the same manner as described in (a). 42) [a] D 19 Ϫ49.9 (cϭ0.6, MeOH). 
H-NMR, IR and MS spectra of this sample were identical to those described in (a). HR-MS (CI
Deconjugative Asymmetric a a-Sulfenylation of (S,E)-and (R,E)-4-Benzyl-3-(2-methyldec-2-enoyl)oxazolidin-2-one (9f, ent-9f). (S)-4-Benzyl-3-[(R,E)-2-(3,3-dimethoxypropylthio)-2-methyldec-3-enoyl]oxazolidin-2-one (11f) and Its Enantiomer (ent-11f) (a) Preparation of 11f:
Treatments of 9f (13.7 g, 40.0 mmol) in a manner similar to that described for the preparation of 11b afforded 11f (9.77 g, 51%) as a colorless oil. To benzyl alcohol (14.0 ml, 135 mmol), titanium isopropoxide (2.0 ml, 6.78 mmol) was added and the resulting mixture was stirred at room temperature for 5 h under a reduced pressure (0.5-1.0 mmHg). The mixture was added to 11b (1.65 g, 4.05 mmol), and the whole was stirred at 70°C for 16 h. After cooling, the mixture was diluted with CH 2 Cl 2 (40 ml) and the reaction was quenched by adding 1 mol/l HCl (10 ml). The insoluble materials which appeared were removed by filtration through a pad of Celite and washed with CH 2 Cl 2 . The filtrates were combined, diluted with H 2 O (20 ml) and extracted with CH 2 Cl 2 (25 mlϫ3). The organic extracts were combined, washed with brine (25 ml), dried over anhydrous Na 2 SO 4 , filtered, and then concentrated in vacuo. Flash column chromatography (hexane/AcOEtϭ10 : 1) of the residue gave 12b (1.21 g, 88%) as a colorless oil. Benzyl 2-(3,3-Dimethoxypropylthio)-2-methylbut-3-enoate (12a Enantiomer (ent-13b) (a) Preparation of 13b: To a solution of 12b (1.19 g, 3.52 mmol) in THF (18 ml), 6% HCl (6.0 ml) was added at room temperature, and the resulting mixture was stirred at the same temperature for 6 h. After quenching the reaction by adding saturated aqueous sodium hydrogen carbonate (30 ml) under cooling in an ice bath, the mixture was extracted with AcOEt (15 mlϫ3 
(R)-
1055). (R,E)-Benzyl 2-Methyl-2-(3-oxopropylthio)hex-3-enoate (13c) and Its
Enantiomer (ent-13c) (a) Preparation of 13c: Treatments of 12c (1.34 g, 3.80 mmol) in a manner similar to that described for the preparation of 13b, afforded 13c (1.14 g, 98%) as a colorless oil. 43 06 mmol) in EtOH (105 ml), a solution of 13b (400 mg, 1.37 mmol) in EtOH (34 ml) was added dropwise at 4°C, and the resulting mixture was stirred at the same temperature for 20 min. The reaction mixture was poured into a mixture of saturated aqueous ammonium chloride solution and 1 mol/l HCl (3 : 1, 120 ml), and the aqueous mixture was extracted with Et 2 O (20 mlϫ3). The organic extracts were combined, dried over anhydrous Na 2 SO 4 , filtered, and then concentrated in vacuo. The residue was diluted with CH 2 Cl 2 (7 ml). Et 3 N (0.3 ml, 2.15 mmol) and propionyl chloride (0.13 ml, 1.46 mmol) were added dropwise to the resulting CH 2 Cl 2 solution at 4°C, and the mixture was stirred at the same temperature for 30 min. After quenching the reaction by adding saturated aqueous ammonium chloride solution (30 ml), the mixture was extracted with CH 2 Cl 2 (20 mlϫ3). The organic extracts were combined, washed with brine (20 ml), dried over anhydrous Na 2 SO 4 , filtered, and then concentrated in vacuo. Flash column chromatography (hexane/AcOEtϭ20 : 1) of the residue gave 14b (295 mg, 74%) as a colorless oil. -2-(propionylthio)hept-3-enoate (14d) -2-(acetylthio)hex-3-enoate (15c) 
(R,E)-Benzyl 2-Methyl
1368). (R,E)-Benzyl 2-Methyl-2-(acetylthio)oct-3-enoate (15e) and Its Enantiomer (ent-15e) (a) Preparation of
1759). (R,E)-4-Hydroxy-3,5-dimethyl-5-(prop-1-enyl)thiophen-2(5H)-one (3b) and Its Enantiomer (ent-3b) (a) Preparation of 3b:
To a solution of 14b (289 mg, 0.988 mmol) in THF (49 ml), LiHMDS (1.0 mol/l solution in THF, 2.5 ml, 2.5 mmol) was added dropwise at Ϫ78°C, and the resulting mixture was allowed to slowly warm to room temperature over 3.5 h. The mixture was poured into a solution of 1 mol/l HCl (40 ml), and the aqueous mixture was extracted with Et 2 O (40 mlϫ3). The organic extracts were combined, dried over anhydrous Na 2 SO 4 , filtered, and then concentrated in vacuo. The residue was added to a saturated aqueous sodium hydrogen carbonate solution (20 ml . The optical purity of ent-3b prepared here was estimated to be Ͼ99% ee using a method similar to that described in (a). . While the optical purity of 3a could not be determined by HPLC analysis, it was calculated to be Ͼ90% ee based on the diastereomeric excess of the corresponding 11a which had been determined as Ͼ90% de by the 1 H-NMR spectra of 11a and its (2ЈS)-diastereomer. 1 
0402). (b) Preparation of ent-3a:
Compound ent-3a (89 mg, 67%) was prepared as a colorless powder from ent-14a (218 mg, 0.783 mmol) in the same manner as described in (a). mp 111-114°C (diisopropyl ether).
[a] D 25 Ϫ38.2 (cϭ0.3, MeOH). The optical purity of ent-3a was calculated to be Ͼ90% ee similar to that for 3a.
1 H-NMR, 13 C-NMR, IR and MS spectra of this sample were identical to those described in (a). HR-MS (EI . While the optical purity of 3c could not be determined by HPLC analysis, it was calculated to be Ͼ90% ee based on the diastereomeric excess of the corresponding 11c which had been determined as Ͼ90% de by the 1 H-NMR spectra of 11c and its (2ЈS)-diastereomer. 1 3, MeOH) . The optical purity of ent-3c was calculated to be Ͼ90% ee similar to that for 3c.
1 H-NMR, 13 
C-NMR, IR and MS spectra of this sample were identical to those described in (a). HR-MS (EI
0715). (R,E)-4-Hydroxy-3,5-dimethyl-5-(pent-1-enyl)thiophen-2(5H)-one (3d)
and Its Enantiomer (ent-3d) (a) Preparation of 3d: Treatments of 14d (234 mg, 0.730 mmol) in a manner similar to that described for the preparation of 3b, afforded 3d (99 mg, 64%) as a colorless crystals. mp 71-73°C (heptane-diisopropyl ether).
[a] D 25 ϩ48.0 (cϭ0.3, MeOH). While the optical purity of 3d could not be determined by HPLC analysis, it was calculated to be Ͼ90% ee based on the diastereomeric excess of the corresponding 11d which had been determined as Ͼ90% de by the 1 H-NMR spectra of 11d and its (2ЈS)-diastereomer. 1 cϭ0.3, MeOH) . The optical purity of ent-3d was calculated to be Ͼ90% ee similar to that for 3d. 1 H-NMR, 13 C-NMR, IR and MS spectra of this sample were identical to those described in (a . The optical purity of ent-3e prepared here was estimated to be 89% ee using a method similar to that described in (a).
1 H-NMR, 13 C-NMR, IR and MS spectra of this sample were identical to those described in (a). HR-MS (EI [a] D 20 Ϫ54.5 (cϭ0.9, MeOH). The optical purity of ent-3f prepared here was estimated to be 84% ee using a method similar to that described in (a).
1 H-NMR, 13 C-NMR, IR and MS spectra of this sample were identical to those described in (a). HR-MS (EI cϭ0.3, MeOH) . The optical purity of ent-4b prepared here was estimated to be Ͼ99% ee using a method similar to that described in (a).
1 H-NMR, 13 C-NMR, IR and MS spectra of this sample were identical to those described in (a). HR-MS (EI . While the optical purity of 4a could not be determined by HPLC analysis, it was calculated to be Ͼ90% ee based on the diastereomeric excess of the corresponding 11a which had been determined as Ͼ90% -1-enyl)-4-hydroxy-5-methylthiophen-2(5H)-one (4c) [a] D 25 Ϫ8.8 (cϭ0.3, MeOH). The optical purity of ent-4c prepared here was estimated to be Ͼ99% ee using a method similar to that described in (a).
1 H-NMR, 13 C-NMR, IR and MS spectra of this sample were identical to those described in (a). HR-MS (EI . The optical purity of ent-4d prepared here was estimated to be Ͼ99% ee using a method similar to that described in (a).
1 H-NMR, 13 C-NMR, IR and MS spectra of this sample were identical to those described in (a). HR-MS (CI prepared here was estimated to be 88% ee using a method similar to that described in (a). 1 H-NMR, 13 C-NMR, IR and MS spectra of this sample were identical to those described in (a). HR-MS (CI . The optical purity of ent-4f prepared here was estimated to be 87% ee using a method similar to that described in (a).
1 H-NMR, 13 C-NMR, IR and MS spectra of this sample were identical to those described in (a). HR-MS (EI 0 mmol) in MeOH (60 ml), sodium methoxide (750 mg, 13.2 mmol) was added at room temperature, and the resulting mixture was stirred at the same temperature for 30 min. Titanium(III) chloride (20% aqueous solution, 37.0 g, 48.0 mmol) was added to the mixture at the same temperature, and the stirring was continued for 3 h at room temperature. The reaction mixture was extracted with Et 2 O (30 mlϫ5). The organic extracts were combined, dried over anhydrous Na 2 SO 4 , filtered, and then concentrated in vacuo. Flash column chromatography (hexane/ AcOEtϭ10 : 1) of the residue gave 16b (1.14 g, 77%) as a colorless oil. 198 mmol) in MeOH (132 ml) was added conc. HCl (0.6 ml) at room temperature and the resulting mixture was stirred at the same temperature for 2 h. The precipitates which appeared were collected by filtration and dried in vacuo to afford NЈ-cyclooctylidene-4-methylbenzenesulfonohydrazide as a white solid (52.7 g, 91%). To a stirred suspension of NЈ-cyclooctylidene-4-methylbenzenesulfonohydrazide (1.00 g, 3.40 mmol) in TMEDA (13.6 ml), n-BuLi (1.6 mol/l in hexane, 4.9 ml, 7.84 mmol) was added dropwise at Ϫ78°C. After the resulting mixture was stirred at room temperature for 30 min, DMF (1.3 ml, 16.8 mmol) was added at 4°C. The reaction mixture was stirred at room temperature for 2 h. After quenching the reaction by adding water, the mixture was extracted with AcOEt (20 mlϫ3). The organic extracts were combined, washed with brine (20 ml), dried over anhydrous Na 2 SO 4 , filtered, and then concentrated in vacuo. Flash column chromatography (hexane/AcOEtϭ20 : 1) of the residue gave 16c (370 mg, 79%) as a colorless oil. 
(E)-3-[(E)-Cyclooctenyl]-2-methylacrylic Acid (17c)
Treatments of 16c (6.91 g, 50.0 mmol) and triethyl 2-phosphonopropionate (13.4 g, 55.1 mmol) in a manner similar to that described for the preparation of 8d, afforded 17c (7. R,E)-4-Benzyl-3-(3-cyclohexenyl-2-methylacryloyl) oxazolidin-2-one (18a) and Its Enantiomer (ent-18a) (a) Preparation of 18a: Treatments of 17a (3.00 g, 18.0 mmol) in a manner similar to that described for the preparation of 9b, afforded 18a (4.73 g, 81%) -3-(3-cyclohexenyl-2-methylacryloyl)oxazolidin-2-one (18a, ent-18a).  (R)-4-Benzyl-3-[(R,E)-3-(cyclohex-2-enylidene)-2-(3,3-dimethoxypropylthio)-2-methylpropanoyl]oxazolidin-2-one (19a) , Its (S,E)-Diastereomer (26a), (R,Z)-Isomer (27a) and Their Enantiomers (ent-19a, ent-26a, ent27a) (a) Preparation of 19a, 26a and 27a: To a solution of 18a (1.30 g, 4.00 mmol) and HMPA (2.8 ml, 16.1 mmol) in THF (20 ml), NaHMDS (1.0 mol/l solution in THF, 4.4 ml, 4.40 mmol) was added dropwise at Ϫ78°C, and the resulting mixture was stirred at the same temperature for 30 min. A solution of 10 (1.14 g, 5.32 mmol) in THF (4 ml) was added to the reaction mixture at the same temperature, and the resulting mixture was allowed to slowly warm to 0°C. After quenching the reaction by adding saturated aqueous ammonium chloride solution (40 ml), the mixture was extracted with AcOEt (40 mlϫ3). The organic extracts were combined, washed with brine (40 ml), dried over anhydrous Na 2 SO 4 , filtered, and then concentrated in vacuo. Flash column chromatography (hexane/AcOEtϭ4 : 1) of the residue gave a mixture of 19a, 26a and 27a (1.70 g, 92%) as an oil.
21 H-NMR, IR and MS spectra of this sample were identical to those described in (a). Although the formation of two types of the by-products ent-26b and ent-27b was anticipated similarly to the case described in (a), their isolation was not attempted.
Deconjugative Asymmetric a a-Sulfenylation of (R,E)-and (S,E)-4-Ben-zyl-3- (3-cyclooctenyl-2-methylacryloyl)oxazolidin-2-one (18c, ent-18c H-NMR, IR and MS spectra of this sample were identical to those described in (a). Although the formation of two types of the by-products ent-26c and ent-27c was anticipated similarly to the case described in (a), their isolation was not attempted. 14b afforded 22b (170 mg, 68%) (cϭ0.3, MeOH) . The optical purity of 5a was calculated to be Ͼ99% ee based on the diastereomeric excess of the corresponding 19a which had been determined as Ͼ99% de by HPLC analysis. 1 -5a (99 mg, 91% ) was prepared as a colorless powder from ent-22a (158 mg, 0.459 mmol) in the same manner as described in (a). mp 107-112°C (cyclohexane).
[a] D 25 Ϫ133 (cϭ0.6, MeOH). The optical purity of ent-5a was estimated to be Ͼ99% ee similarly to case for 5a. . The optical purity of 5b was calculated to be Ͼ99% ee based on the diastereomeric excess of the corresponding 19b which had been determined as Ͼ99% de by HPLC analysis. [a] D 27 Ϫ92.9 (cϭ0.2, MeOH). The optical purity of ent-5b was estimated to be Ͼ99% ee similarly to case for 5b.
1 H-NMR, 13 C-NMR, IR and MS spectra of this sample were identical to those described in (a). . The optical purity of 5c was calculated to be Ͼ99% ee based on the diastereomeric excess of the corresponding 19c which had been determined as Ͼ99% de by HPLC analysis. 1 . The optical purity of ent-5c was estimated to be Ͼ99% ee similarly to case for 5c. [a] D 27 ϩ138 (cϭ0.2, MeOH). The optical purity of 6a was calculated to be Ͼ99% ee based on the diastereomeric excess of the corresponding 19a which had been determined as Ͼ99% de by HPLC analysis. 27 Ϫ133 (cϭ0.6, MeOH). The optical purity of ent-6a was estimated to be Ͼ99% ee similarly to the case for 6a.
HR-MS (EI
1 H-NMR, 13 C-NMR, IR and MS spectra of this sample were identical to those described in (a . The optical purity of ent-6b was estimated to be Ͼ99% ee similarly to the case for 6b.
1 H-NMR, 13 C-NMR, IR and MS spectra of this sample were identical to those described in (a). HR-MS (EI . The optical purity of 6c was calculated to be Ͼ99% ee based on the diastereomeric excess of the corresponding 19c which had been determined as Ͼ99% de by HPLC analysis. . The optical purity of ent-6c was estimated to be Ͼ99% ee similarly to the case for 6c.
1 H-NMR, 13 C-NMR, IR and MS spectra of this sample were identical to those described in (a). HR-MS (EI Biological Assay In vitro antibacterial activity assay: The minimum inhibitory concentration (MIC) (mg/ml) was determined by the ager dilution method 22) with Muller-Hinton agar (Difco Laboratories, Detroit, MI, U.S.A.). The MIC was defined as the lowest concentration of an antibacterial agent that inhibited visible growth after incubation at 35°C for 18 h.
In vitro inhibitory activity assay for mammalian type I fatty acid synthase: Fatty acid synthesis was evaluated by measuring the incorporation of [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C] acetate into cellular fatty acid as previously described 23) with some modification. Human HepG2 cells were seeded in a 12-well plate and cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin in a 5% CO 2 atmosphere at 37°C for 24 h. The medium was removed and replaced with serum-free DMEM. After 24 h incubation, the cells were treated with various concentrations of the test compound for 4 h in KrebsRinger phosphate HEPES buffer (pH 7.4). [1- 14 C] acetate (0.4 uCi/ml; 56.5 mCi/mmol; Perkin-Elmer Inc., Norwalk, CT, U.S.A.) was added to the medium, which was then incubated at 37°C for 2 h. The metabolic reaction was stopped by the addition of ethanolic KOH, and the samples were left at 80°C for 2 h. After extracting nonsaponifiable lipids with petroleum ether, the water-soluble residual layer was acidified to pH Ͻ1 by the addition of HCl. Total fatty acids were extracted with petroleum ether, and the combined organic extracts were dried and concentrated in vacuo. The residue was dissolved with methanol and was transferred into a scintillaton vial. Radioactivity of total fatty acids was counted by a liquid scintillation counter (Perkin-Elmer Inc.). IC 50 values were calculated by the auto-analysis program GraphPad Prism, version 4.00 (GraphPad Software Inc., La Jolla, CA, U.S.A.).
